Back to Search
Start Over
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
- Source :
- Blood Cancer Journal, Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
- Subjects :
- Adult
Male
medicine.medical_specialty
Follicular lymphoma
Lymphoproliferative disorders
Antibodies, Viral
Gastroenterology
Article
Antibodies
Antibody Specificity
hemic and lymphatic diseases
Internal medicine
medicine
Humans
Longitudinal Studies
Seroconversion
Prospective cohort study
RC254-282
Multiple myeloma
Aged
Aged, 80 and over
Haematological cancer
biology
SARS-CoV-2
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
COVID-19
Hematology
Middle Aged
medicine.disease
Immunity, Humoral
Lymphoma
Hospitalization
Italy
Oncology
Case-Control Studies
Hematologic Neoplasms
Antibody Formation
biology.protein
Female
Rituximab
Antibody
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 20445385
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Blood Cancer Journal
- Accession number :
- edsair.doi.dedup.....84b2622e838d8e2596a78c6efa1b9a63
- Full Text :
- https://doi.org/10.1038/s41408-021-00546-9